NovoCure Limited Ordinary Shares (NVCR) Stock Price

NVCRStock

$17.62+34.84%52W

Market Cap$2.05B

P/E—

PEG Ratio—

Div yield—

Beta1.01

NVCR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)35.77%

Price vs S&P 500 (4W)-0.29%

VGM Score47.48

Book Value / Share (Quarterly)$2.90

P/TBV (Annual)3.02x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)6.81%

Cash Flow / Share (Quarterly)$-0.22

Price vs S&P 500 (YTD)17.66%

Gross Margin (TTM)76.13%

Net Profit Margin (TTM)-21.25%

EPS (TTM)$-1.31

10-Day Avg Trading Volume1.41M

EPS Excl Extra (TTM)$-1.31

Revenue Growth (5Y)5.80%

EPS (Annual)$-1.22

ROI (Annual)-25.44%

Gross Margin (Annual)74.54%

Net Profit Margin (5Y Avg)-23.48%

Cash / Share (Quarterly)$3.78

Revenue Growth QoQ (YoY)15.60%

ROA (Last FY)-16.94%

Revenue Growth TTM (YoY)10.95%

EBITD / Share (TTM)$-1.22

ROE (5Y Avg)-35.83%

Operating Margin (TTM)-22.08%

Cash Flow / Share (Annual)$-0.67

P/B Ratio6.05x

P/B Ratio (Quarterly)5.19x

Net Income / Employee (Annual)$-84,900

EV / Revenue (TTM)3.07x

Net Interest Coverage (TTM)-15.06x

ROA (TTM)-15.85%

EV / EBITDA (TTM)1866.94x

EPS Incl Extra (Annual)$-1.22

Current Ratio (Annual)2.90x

Quick Ratio (Quarterly)2.70x

3-Month Avg Trading Volume1.71M

52-Week Price Return34.84%

Revenue / Employee (TTM)$435,600

Tangible BV / Share (Quarterly)$3.69

P/S Ratio (Annual)3.12x

Asset Turnover (Annual)0.81x

52-Week High$21.45

Operating Margin (5Y Avg)-24.46%

EPS Excl Extra (Annual)$-1.22

CapEx CAGR (5Y)12.22%

Tangible BV CAGR (5Y)31.18%

26-Week Price Return47.02%

Quick Ratio (Annual)2.57x

13-Week Price Return-6.37%

Total Debt / Equity (Annual)0.57x

Current Ratio (Quarterly)2.89x

Enterprise Value$2.15B

Revenue / Share Growth (5Y)5.31%

Asset Turnover (TTM)0.75x

Book Value / Share Growth (5Y)-8.26%

Revenue / Employee (Annual)$408,300

Inventory Turnover (Annual)4.38x

Pretax Margin (Annual)-20.79%

Cash / Share (Annual)$3.98

3-Month Return Std Dev92.56%

Gross Margin (5Y Avg)76.78%

Net Income / Employee (TTM)$-92,600

ROE (Last FY)-40.01%

Net Interest Coverage (Annual)-20.92x

EPS Basic Excl Extra (Annual)$-1.22

P/FCF (TTM)126.73x

Receivables Turnover (TTM)7.59x

Total Debt / Equity (Quarterly)0.58x

EPS Incl Extra (TTM)$-1.31

Receivables Turnover (Annual)8.01x

ROI (TTM)-22.07%

P/S Ratio (TTM)2.92x

Pretax Margin (5Y Avg)-21.01%

Revenue / Share (Annual)$5.88

Tangible BV / Share (Annual)$4.20

Price vs S&P 500 (52W)16.52%

Year-to-Date Return29.62%

5-Day Price Return-2.78%

EPS Normalized (Annual)$-1.22

ROA (5Y Avg)-12.30%

Net Profit Margin (Annual)-20.79%

Month-to-Date Return12.94%

Cash Flow / Share (TTM)$-1.76

EBITD / Share (Annual)$-1.25

Operating Margin (Annual)-23.47%

LT Debt / Equity (Annual)0.57x

ROI (5Y Avg)-15.89%

LT Debt / Equity (Quarterly)0.58x

EPS Basic Excl Extra (TTM)$-1.31

P/TBV (Quarterly)3.38x

P/B Ratio (Annual)4.25x

Inventory Turnover (TTM)4.00x

Pretax Margin (TTM)-21.84%

Book Value / Share (Annual)$3.03

Price vs S&P 500 (13W)-9.16%

Beta1.01x

P/FCF (Annual)216.84x

Revenue / Share (TTM)$6.03

ROE (TTM)-44.00%

52-Week Low$9.82

vGradeD

gGradeC

mGradeC

vgmGradeC

NVCR Earnings Surprise History

Q2 25-0.36est. -0.39

Q3 25-0.33est. -0.42

Q4 25-0.22est. -0.41

Q1 26-0.62est. -0.51

Q2 26-0.13est. -0.33

NVCR Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.08

3.92

Industry Peers — Surgical & Medical Instruments(140)

Symbol	Value Score	Growth Score	Momentum Score	Price
NVCRNovoCure Limited Ordinary Shares	D	C	C	$17.62
SYKStryker Corporation	C	B	C	$330.59
MMM3M Company	C	D	B	$179.37
BSXBoston Scientific Corp.	C	B	D	$49.86
BDXBecton, Dickinson and Co.	B	D	B	$189.78
MDLNMedline Inc. Class A common stock	C	D	C	$35.64
RMDResMed Inc.	C	B	C	$236.59
DXCMDexCom, Inc.	D	B	B	$89.16
WSTWest Pharmaceutical Services, Inc.	D	C	B	$348.48
SOLVSolventum Corporation	C	C	B	$91.61
BAXBaxter International Inc.	B	D	B	$26.29
PENPenumbra, Inc.	D	C	C	$324.37
GMEDGLOBUS MEDICAL INC	B	B	C	$82.96
GKOSGlaukos Corporation	F	A	A	$181.39
PODDInsulet Corporation	C	A	D	$143.05
STVNStevanato Group S.p.A.	D	C	B	$22.70
TFXTeleflex Incorporated	B	F	B	$140.18
MMSIMerit Medical Systems Inc	C	B	B	$91.09
MMEDMiniMed Group, Inc. Common Stock	—	—	A	$18.92
HAEHaemonetics Corporation	C	C	A	$108.32
ICUIICU Medical Inc	C	D	B	$182.24
HTFLHeartflow, Inc. Common Stock	—	A	A	$49.89
IRTCiRhythm Holdings, Inc. Common Stock	F	A	C	$123.09
PLSEPulse Biosciences, Inc Common Stock (DE)	F	—	A	$49.00
ATRCAtriCure, Inc.	D	B	A	$48.68
UFPTUFP Technologies Inc	C	B	B	$304.21
LMATLeMaitre Vascular, Inc.	C	B	D	$78.97
INSPInspire Medical Systems, Inc.	B	B	B	$61.07
KMTSKestra Medical Technologies, Ltd. Common Stock	F	A	B	$26.92
TNDMTandem Diabetes Care, Inc.	D	C	B	$21.58
ATECAlphatec Holdings, Inc.	D	B	C	$9.33
DRTSAlpha Tau Medical Ltd. Ordinary Shares	—	—	A	$14.70
IARTIntegra LifeSciences Holdings	B	D	C	$16.79
AORTArtivion, Inc.	C	C	C	$26.38
PRCTPROCEPT BioRobotics Corporation Common Stock	C	A	D	$21.60
IRMDiRadimed Corporation	D	B	C	$87.87
BVSBioventus Inc. Class A Common Stock	B	C	A	$14.08
SGPSpyGlass Pharma, Inc. Common Stock	—	—	B	$26.60
SIBNSI-BONE, Inc. Common Stock	D	B	B	$19.54
BBNXBeta Bionics, Inc. Common Stock	D	A	A	$19.34
SSIISS Innovations International Inc. Common Stock	F	A	D	$3.55
ANGOAngioDynamics, Inc.	C	D	B	$15.95
KIDSOrthoPediatrics Corp. Common Stock	C	B	B	$24.50
MDXGMiMedx Group, Inc	C	D	C	$4.34
DCTHDelcath Systems Inc	D	B	A	$16.92
BWAYBrainsway Ltd. American Depositary Shares	F	A	C	$14.43
CERSCerus Corp	D	C	B	$2.72
TCMDTactile Systems Technology, Inc.	B	B	C	$23.58
CLPTClearPoint Neuro, Inc. Common Stock	F	A	B	$16.96
NPCENeuropace, Inc. Common Stock	D	C	C	$14.16
SIShoulder Innovations, Inc.	—	B	A	$22.32

About NovoCure Limited Ordinary Shares

NovoCure Ltd is an oncology company that develops and commercializes Tumor Treating Fields (TTFields) devices, a proprietary technology platform for treating solid tumors. The company's approved products, Optune Gio and Optune Lua, treat glioblastoma, non-small cell lung cancer, and pancreatic cancer, while its pipeline includes Trident, Lunar-2, Panova-3, and Metis candidates. With headquarters in the United States, NovoCure generates the majority of its revenue domestically, with additional sales from Germany, Japan, and other international markets.